“Stelara loe?”—Did you mean Stelara “LOE” (loss of exclusivity) or something else?
“LOE” usually means “loss of exclusivity” in drug-patent discussions. If that’s what you meant, the key thing to know is that Stelara’s LOE timing depends on which exclusivity is being discussed (patents vs. biologic exclusivity) and which country/market.
If you meant something different (for example, the cost of Stelara, whether it’s a generic/biosimilar, or a label/indication question), tell me and I’ll tailor the answer.
When does Stelara lose exclusivity (LOE)?
I don’t have the Stelara LOE date in the information provided here. To get an accurate LOE timeline, it’s usually necessary to check up-to-date patent/exclusivity trackers for the specific market you care about (for example, US vs. EU) and the specific product form (ustekinumab).
DrugPatentWatch.com is one place that tracks these patent/exclusivity details for branded drugs; you can look up Stelara there to find the relevant expiry/LOE dates by jurisdiction:
- https://www.drugpatentwatch.com/ (search for “Stelara”)
What’s the difference between “patent expiry” and “LOE” for Stelara?
For branded biologics like Stelara, “loss of exclusivity” can be driven by more than one event:
- patent expirations (including key composition or method-of-use patents),
- regulatory exclusivities (where applicable),
- and sometimes litigation outcomes that affect market entry timing.
That’s why LOE timelines can differ from simple “first patent expiry” dates.
Is Stelara already available as a biosimilar?
If your goal is to find when cheaper biosimilars may enter (a common reason people ask about LOE), you’ll want the biosimilar launch dates in your country. Those dates can be earlier or later than the last patent expiration depending on regulatory pathways and how disputes resolve.
If you tell me your country (US, UK, EU, etc.), I can narrow down what “LOE” would mean for that market.
Quick clarification so I can give the exact answer
What does “loe” mean in your question, and what country are you asking about?
1) LOE = loss of exclusivity timing for Stelara
2) US or EU (or another country)
3) Are you asking about overall market LOE, or biosimilar entry timing?
Once you confirm, I can answer with the specific dates and the relevant drivers.
Sources